The value of mesothelin in the diagnosis and follow-up of surgically treated ovarian cancer

Objective: To assess the value of serum mesothelin concentration for diagnosis of ovarian cancer and for monitoring the therapeutic effect of surgical treatment. Materials and Methods: The study consisted of 42 patients with ovarian cancer undergoing surgery, 48 with benign ovarian tumors, and 49 healthy controls. Blood was drawn pre-operatively and one month post-operatively to test serum mesothelin levels. Results: Mesothelin values were higher in the ovarian cancer group compared to controls and higher preoperatively vs post-operatively in the ovarian cancer group. For the diagnosis of ovarian cancer, the positive predictive value of serum mesothelin was 80.5%, the negative predictive value was 81.6%, sensitivity was 78.6%, and specificity was 83.3%. Conclusion: Serum mesothelin is increased in ovarian cancer, has high-specificity, and can be used in the pre-operative diagnostic evaluation for ovarian cancer.

Mesothelin; Ovarian cancer.

[1] Jemal A., Twari R.C., Murray T., Ghafoor A., Samuels A., Ward E. et al.: “Cancer statistics, 2004”. CA Cancer J. Clin., 2004, 54, 8.

[2] Young R.C., Walton L.A., Ellenberg S.S., Homesley H.D., Wilbanks G.D., Decker D.G. et al.: “Adjuvant therapy in Stage I and Stage II epithelial ovarian cancer”. N. Engl. J. Med., 1990, 322, 1021.

[3] Bast R.C., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H. et al.: “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer”. N. Engl. J. Med., 1983, 309, 883.

[4] Jacobs I.J., Skates S.J., MacDonald N., Menon U., Rosenthal A.N., Davies A.P. et al.: “Screening for ovarian cancer: a pilot randomised controlled trial”. Lancet, 1999, 353, 1207.

[5] Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M. et al.: “Use of proteomic patterns in serum to identify ovarian cancer”. Lancet, 2002, 359, 572.

[6] Sasaroli D., Coukos G., Scholler N.: “Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?”. Biomark Med., 2009, 3, 275.

[7] Cohen L.S., Escobar P.F., Scharm C., Glimco B., Fishman D.A.: “Three dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction”. Gynecol. Oncol., 2001, 82, 40.

[8] Hellström I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M. et al.: “The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma”. Cancer Res., 2003, 63, 3695.

[9] Havrilesky L.J., Whitehead C.M., Rubatt J.M., Cheek R.L., Groelke J., He Q. et al.: “Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence”. Gynecol. Oncol., 2008, 110, 374.

[10] Anastasi E., Marchei G.G., Viggiani V., Gennarini G., Frati L., Reale M.G.: “HE4: a new potential early biomarker for the recurrence of ovarian cancer”. Tumour Biol., 2010, 31, 113.

[11] Hellström I., Hellström K.E.: “Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma”. Expert. Opin. Med. Diagn., 2011, 5, 227.

[12] Palmer C., Duan X., Hawley S., Scholler N., Thorpe J.D., Sahota R.A. et al.: “Systematic evaluation of candidate blood markers for detecting ovarian cancer”. PLoS One, 2008, 3, e2633.

[13] Creaney J., Yeoman D., Naumoff L.K., Hof M., Segal A., Musk A.W. et al.: “Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma”. Thorax, 2007, 62, 569.

[14] Creaney J., Musk A.W., Robinson B.W.: “Sensitivity of urinary mesothelin in patients with malignant mesothelioma”. J. Thorac. Oncol., 2010, 5, 1461.